 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12345678910111213...266267» |
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed: iFOCUS: Treatment of Cancer with Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound Histotripsy (clinicaltrials.gov) - Jan 7, 2025
P1, N=24, Active, not recruiting, Sponsor: UMC Utrecht
Recruiting --> Active, not recruiting
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (clinicaltrials.gov) - Jan 7, 2025
P2, N=218, Recruiting, Sponsor: Melanoma Institute Australia
Recruiting --> Active, not recruiting Trial completion date: Aug 2025 --> Aug 2029 | Trial primary completion date: Aug 2024 --> Aug 2026
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, Trial completion date, Trial primary completion date, Checkpoint inhibition: Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors (clinicaltrials.gov) - Jan 3, 2025
P2, N=5, Completed, Sponsor: Children's National Research Institute
Trial completion date: Aug 2025 --> Aug 2029 | Trial primary completion date: Aug 2024 --> Aug 2026 Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Mar 2024 | Trial primary completion date: Jul 2025 --> Mar 2024
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, PD(L)-1 Biomarker, Metastases: Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. (Pubmed Central) - Jan 3, 2025
P3
The final trial results showed a continued, ongoing survival benefit with nivolumab plus ipilimumab and with nivolumab monotherapy, as compared with ipilimumab monotherapy, in patients with advanced melanoma. (Funded by Bristol Myers Squibb and others; CheckMate 067 ClinicalTrials.gov number, NCT01844505.).
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal: Primary Treatment of Eyelid Conjunctival Melanoma with Immunotherapy: A Case Report. (Pubmed Central) - Jan 3, 2025
Herein, the authors present the case of metastatic palpebral conjunctival melanoma in a 59-year-old male successfully treated with a first-line combination of ipilimumab and nivolumab without adjuvant therapies or local surgeries. Local disease resolution was achieved after only 7 months of treatment, and the immune checkpoint inhibitor regimen was well-tolerated with limited systemic adverse effects and no ocular side effects.
- | Journal, PD(L)-1 Biomarker, IO biomarker: European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024. (Pubmed Central) - Jan 3, 2025
In resected stage IV, nivolumab can be offered, as well as ipilimumab and nivolumab, in selected, high-risk patients...Neoadjuvant therapy with pembrolizumab followed by complete surgical resection and adjuvant pembrolizumab is also recommended...Other second line therapies include therapy with tumor infiltrating lymphocytes and combinations of immune checkpoint inhibitors not used in first line. This guideline is valid until the end of 2026.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New trial: Omitting Therapeutic Lymph Node Dissection in Patients with Melanoma (stage 3) and Major Pathological Response in the Index Lymph Node (clinicaltrials.gov) - Jan 3, 2025
P=N/A, N=213, Not yet recruiting, Sponsor: D.J. (Dirk) Gr
- GRANITE / Gritstone bio
Trial withdrawal, Checkpoint inhibition: Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer (clinicaltrials.gov) - Jan 3, 2025
P2, N=0, Withdrawn, Sponsor: Gritstone bio, Inc.
This guideline is valid until the end of 2026. Terminated --> Withdrawn
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Retrospective data, Journal, Real-world evidence: Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan. (Pubmed Central) - Dec 27, 2024
To our knowledge, this is the largest study that evaluates Japanese patients with mRCC receiving NIVO + IPI treatment. In this study, the real-world oncological outcomes after NIVO + IPI treatment were comparable to those in the CheckMate 214 study.
- || Voyager-V1 / Vyriad
Trial completion date, Trial primary completion date: Ph I/II Trial of Systemic VSV-IFN?-NIS in Combination with Checkpoint Inhibitor Therapy in Patients with Select Solid Tumors (clinicaltrials.gov) - Dec 27, 2024
P1/2, N=86, Recruiting, Sponsor: Vyriad, Inc.
In this study, the real-world oncological outcomes after NIVO + IPI treatment were comparable to those in the CheckMate 214 study. Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date: IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients (clinicaltrials.gov) - Dec 27, 2024
P2, N=29, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025 Trial primary completion date: Nov 2024 --> Aug 2025
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, Monotherapy: CheckMate 032: A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Dec 26, 2024
P1/2, N=1163, Completed, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Nov 2024 --> Aug 2025 Active, not recruiting --> Completed
- |||| Zejula (niraparib) / GSK, J&J, Yervoy (ipilimumab) / BMS
New P2 trial: ParpVax2: Maintenance Niraparib Plus Ipilimumab in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy (clinicaltrials.gov) - Dec 26, 2024
P2, N=68, Not yet recruiting, Sponsor: Abramson Cancer Center at Penn Medicine
- ||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, Trial completion date: CheckMate 9LA: A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (clinicaltrials.gov) - Dec 26, 2024
P3, N=719, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Oct 2024
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, Trial completion date, Trial primary completion date: Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer (clinicaltrials.gov) - Dec 26, 2024
P2, N=64, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Oct 2024 Active, not recruiting --> Completed | Trial completion date: May 2025 --> Dec 2024 | Trial primary completion date: May 2025 --> Dec 2024
- || Review, Journal: Literature review Analysis of the Current State of Targeted Therapy for Gastrointestinal Cancers. (Pubmed Central) - Dec 24, 2024
These advanced tumors are treated with targeted drugs for GI malignancies, and it is now common knowledge that patients must be identified through routine molecular profiling. This article provided a clinical summary of the most recent advances in targeted treatment for GEC and the supporting clinical data, such as their efficacy and safety profiles.
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
P2 data, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial. (Pubmed Central) - Dec 22, 2024
This article provided a clinical summary of the most recent advances in targeted treatment for GEC and the supporting clinical data, such as their efficacy and safety profiles. Results showed antitumour activity and manageable safety with NIVO
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Biomarker, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Efficacy and prognostic factors of anti-PD1 and nivolumab-ipilimumab therapy in advanced melanoma patients resistant to prior ICI treatment. (Pubmed Central) - Dec 20, 2024
Anti-PD-1 therapy demonstrated efficacy following resistance to anti-CTLA-4, whereas combination ICI therapy showed lower response rates in patients resistant to anti-PD-1. Further studies are needed to confirm the RMH scores and other prognostic markers and to evaluate subgroups with lower efficacy of nivolumab-ipilimumab therapy.
- | Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, Checkpoint inhibition, Metastases: Impact of Tobacco, Marijuana, and Alcohol Use on Overall Survival in Recurrent Metastatic Head and Neck Cancer Patients Treated With Immune Checkpoint Inhibitors. (Pubmed Central) - Dec 20, 2024
Further studies are needed to confirm the RMH scores and other prognostic markers and to evaluate subgroups with lower efficacy of nivolumab-ipilimumab therapy. In our cohort, smoking status, marijuana use, and alcohol consumption did not have a statistically significant impact on OS in patients with R/M HNSCC treated with ICI.
- ||| Imfinzi (durvalumab) / AstraZeneca, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Retrospective data, Journal, Adverse events, Checkpoint inhibition: Cutaneous adverse events due to checkpoint inhibitors - a retrospective analysis at a tertiary referral hospital in Switzerland 2019-2022. (Pubmed Central) - Dec 20, 2024
The most frequently observed ir-cAEs were pruritus, maculopapular exanthema and xerosis cutis. In general, the dermatological manifestations are mild and responsive to topical treatment or self-limiting with no requirement for treatment interruption.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Retrospective data, Journal, Metastases: Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma. (Pubmed Central) - Dec 20, 2024
In this retrospective follow-up analysis, we observed a response rate of 67% and long-lasting responses after re-exposition to combined ICI in metastatic MCC patients with progression after initial response or disease control upon their first IPI/NIVO treatment. An important observation from this small analysis is that primary resistance to PD-L1 inhibition may result in a better response to IPI/NIVO.
- | Journal, Real-world evidence, Real-world, Metastases: Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma. (Pubmed Central) - Dec 20, 2024
These findings provide important insights into racial differences in first-line aRCC treatment outcomes within real-world settings. Additional research with larger sample sizes is warranted.
- ||| Yervoy (ipilimumab) / BMS
Biomarker, Journal, Adverse events, IO biomarker, Metastases: Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival. (Pubmed Central) - Dec 20, 2024
These findings indicate that the first dose of ipilimumab induces a systemic response with increased levels of circulating cytokines and suggest candidate biomarkers for clinical response, immune-mediated toxicity and survival. Further studies in independent patient cohorts are required to confirm the findings.
- || Review, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker, Checkpoint block: Fc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology. (Pubmed Central) - Dec 20, 2024
For anti-PD(L)1 antibodies, where a pure antagonistic function ("checkpoint blockade") is sufficient, some mAbs are IgG1 but have been mutated in their Fc sequence (e.g., durvalumab and atezolizumab) or are IgG4 (e.g., nivolumab and pembrolizumab) to have low affinity for Fc?R. Here, we review the impact of Fc?R effector function on immune checkpoint blockers safety and efficacy in oncology.
- | Opdivo (nivolumab) / BMS
Journal: Immuno-mediated colitis induced by nivolumab that mimics endoscopically and histologically an ulcerative colitis. (Pubmed Central) - Dec 20, 2024
Colonoscopy revealed continuous mucosal inflammation up to the cecum, erosions, exudates, and loss of the vascular pattern. Biopsies showed signs of active colitis, cryptic abscesses, and focal cryptitis, all consistent with a case of immuno-mediated colitis induced by Nivolumab that mimics, both endoscopically and histologically, the findings found in ulcerative colitis.
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Clinical data, Journal: Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab. (Pubmed Central) - Dec 19, 2024
Our study identified baseline CXCL6, IL-23, and IL-10 as predictors of response to aCTLA4/aPD1 combination therapy among patients with metastatic melanoma. This study also provides a framework for identifying patients who are likely to respond to combination ICB, as well as a subset of patients with high risk of developing resistance and are thus in need of alternative therapeutic options, such as clinical trials.
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Clinical, P2 data, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical Trial. (Pubmed Central) - Dec 19, 2024
P2
However, the signal observed in ATC may merit further evaluation. ClinicalTrials.gov Identifier: NCT03246958.
- | Enrollment change, Trial completion date, IO biomarker: Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer (clinicaltrials.gov) - Dec 19, 2024
P2, N=9, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT03246958. N=27 --> 9 | Trial completion date: Oct 2024 --> Dec 2025
- Yervoy (ipilimumab) / BMS
Long-Term Results of Ipilimumab Alternating with Lenalidomide in Patients with Relapsed Lymphoma Who Underwent Hematopoietic Cell Transplantation (HCC Exhibit Hall 3; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_1278;
The use of Ipi+LEN after HCT for high-risk lymphoma shows encouraging long-term survival rates. The favorable outcome in patients with MYC/BCL2 DEL/DHL needs to be verified in a larger number of patients.
- Yervoy (ipilimumab) / BMS
Prevalence and Prognostic Significance of Extramedullary AML Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation (HCC Exhibit Hall 3; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_815;
We identify post-HCT EM AML relapses in approximately a third of all post-HCT relapses with EM only relapses occurring significantly later and with longer survival as compared to BM only relapses. Additional work is needed to define the cellular and molecular differences between these different manifestations of AML to better understand mechanisms of response to therapy, guide future treatments, and inform clinical trials.
- MODULE 4: Promising Investigational Front-Line Strategies for Advanced HCC (San Francisco Marriott Marquis, Golden Gate Ballroom ) - Dec 19, 2024 - Abstract #ASCOGI2025ASCO_GI_993;
Additional work is needed to define the cellular and molecular differences between these different manifestations of AML to better understand mechanisms of response to therapy, guide future treatments, and inform clinical trials. This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Eisai Inc.
- |||||||||| IMA203 / Immatics
New P3 trial, Metastases: SUPRAME-ACTengine (clinicaltrials.gov) - Dec 19, 2024
P3, N=360, Not yet recruiting, Sponsor: Immatics US, Inc.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Retrospective data, Journal, Monotherapy, PD(L)-1 Biomarker, IO biomarker: Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients. (Pubmed Central) - Dec 18, 2024
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Eisai Inc. Clinical response evaluated in the first months of therapy is a strong predictor of long-term survival, even in patients with poor prognostic biomarkers.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, PD(L)-1 Biomarker, IO biomarker, Surgery: Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo. (Pubmed Central) - Dec 18, 2024
These data suggest that TLND and adjuvant therapy may be safely omitted in most patients achieving an MPR, while adjuvant systemic therapy following TLND appears to improve RFS and DMFS in patients with pNR. Although these results are hypothesis-generating and require further validation, they offer a potential foundation for developing personalized neoadjuvant immunotherapy approaches.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, Tumor mutational burden: NCI-2018-01560: Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma (clinicaltrials.gov) - Dec 18, 2024
P1/2, N=38, Recruiting, Sponsor: National Cancer Institute (NCI)
Although these results are hypothesis-generating and require further validation, they offer a potential foundation for developing personalized neoadjuvant immunotherapy approaches. Trial completion date: Dec 2024 --> Nov 2025 | Trial primary completion date: Dec 2024 --> Nov 2025
- || CIML NK - Dana / Farber Cancer Institute
Trial completion, Combination therapy, Metastases, Immune cell: CIML NK Cell in Head & Neck Cancer (clinicaltrials.gov) - Dec 18, 2024
P1, N=11, Completed, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Dec 2024 --> Nov 2025 | Trial primary completion date: Dec 2024 --> Nov 2025 Active, not recruiting --> Completed
- | Opdivo (nivolumab) / BMS, Aliqopa (copanlisib) / Bayer, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma (clinicaltrials.gov) - Dec 18, 2024
P1, N=64, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial completion date: Jul 2024 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2026
- ||| Tibsovo (ivosidenib) / Servier
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma (clinicaltrials.gov) - Dec 17, 2024
P1/2, N=7, Completed, Sponsor: Servier Bio-Innovation LLC
Trial completion date: Jul 2024 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2026 Active, not recruiting --> Completed | N=92 --> 7 | Trial completion date: Mar 2026 --> Nov 2024 | Trial primary completion date: Mar 2026 --> Nov 2024
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Neoadjuvant chemoradiotherapy with ipilimumab and nivolumab in rectal cancer (CHINOREC): A prospective randomized, open-label, multicenter, phase II clinical trial. (Level 1, West Hall; Poster Bd #: E25) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_809;
P2
Clinical Trial Registration Number: NCT04124601. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Nivolumab plus ipilimumab (N+I) in patients (pts) with pancreatic cancer (PC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. (Level 1, West Hall; Poster Bd #: H3) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_582;
P2
Clinical Trial Registration Number: NCT02693535. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Nivolumab plus ipilimumab in advanced hepatocellular carcinoma with Child-Pugh B: A multicenter retrospective study. (Level 1, West Hall; Poster Bd #: B3) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_461;
The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Organ-specific responses to nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma: A multicenter, retrospective study. (Level 1, West Hall; Poster Bd #: A21) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_453;
The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW. (Level 2, Ballroom) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_174;
P3
Clinical Trial Registration Number: NCT04008030. The abstract will be released to the public on January 25, 2025 at 3:00 PM UTC
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses. (Level 2, Ballroom) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_161;
P3
Clinical Trial Registration Number: NCT04039607. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- | Dupixent (dupilumab) / Sanofi, Regeneron, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal: Nivolumab and ipilimumab-induced eosinophilic granulomatosis with polyangiitis in a patient treated with dupilumab. (Pubmed Central) - Dec 16, 2024
The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC No abstract available
- |||| BMS-986249 / BMS, Opdivo (nivolumab) / BMS
Trial completion, Enrollment change: A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors (clinicaltrials.gov) - Dec 16, 2024
P1/2, N=607, Completed, Sponsor: Bristol-Myers Squibb
No abstract available Active, not recruiting --> Completed | N=425 --> 607
- | Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: Rate of response to immune checkpoint inhibitor therapy in patients with conjunctival melanoma. (Pubmed Central) - Dec 15, 2024
In 14 patients (88%), orbital exenteration or additional extensive surgery was avoided; two patients had progression despite ICI and eventually needed an orbital exenteration. Future studies should aim to correlate biomarker data with response to ICI therapy in patients with conjunctival melanoma.
- || linrodostat (BMS-986205) / BMS, Ono Pharma, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
P1/2 data, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined With Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies. (Pubmed Central) - Dec 13, 2024
Future studies should aim to correlate biomarker data with response to ICI therapy in patients with conjunctival melanoma. Linrodostat + nivolumab
- || relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, Tumor mutational burden, IO biomarker: CA224-056: Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer (clinicaltrials.gov) - Dec 13, 2024
P2, N=80, Recruiting, Sponsor: Dan Zandberg
Linrodostat + nivolumab Trial completion date: Sep 2027 --> Sep 2026 | Trial primary completion date: May 2027 --> May 2026
- || Clinical, Journal, PD(L)-1 Biomarker, IO biomarker: First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study. (Pubmed Central) - Dec 12, 2024
Notably, patients with favorable-risk disease may derive more benefit from VEGF-TT than from IO therapies in this setting. Future approaches utilizing radiographic tools and biomarker-based liquid biopsies are warranted to detect occult metastatic disease and identify candidate patients for adjuvant IO therapy.